Genprex regains Nasdaq minimum bid price compliance; delisting risk resolved

Genprex, Inc.

Received Nasdaq letter on Nov 4, 2024 confirming compliance with Listing Rule 5550(a)(2).
Previously notified of non-compliance on Sept 26, 2024 due to bid price below $1.00 for 30 consecutive days.
Matter is now closed; company continues trading on Nasdaq Capital Market.

item 8.01 item 9.01

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-033217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.